vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and MACROGENICS INC (MGNX). Click either name above to swap in a different company.
MACROGENICS INC is the larger business by last-quarter revenue ($41.2M vs $30.1M, roughly 1.4× Dominari Holdings Inc.). On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 113.0%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 112.8%).
MacroGenics Inc is a clinical-stage biopharmaceutical firm specializing in the research and development of novel immunotherapies for cancer and autoimmune disorders. Its core product pipeline centers on monoclonal antibody-based treatments, with key programs targeting solid tumors and hematological malignancies, supported by partnerships with global pharmaceutical partners.
DOMH vs MGNX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $41.2M |
| Net Profit | $-131.8M | — |
| Gross Margin | — | — |
| Operating Margin | -8.9% | -29.3% |
| Net Margin | -438.1% | — |
| Revenue YoY | 220.4% | 113.0% |
| Net Profit YoY | -12426.2% | — |
| EPS (diluted) | $-6.94 | $-0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $41.2M | ||
| Q3 25 | $50.8M | $72.8M | ||
| Q2 25 | $34.1M | $22.2M | ||
| Q1 25 | $8.1M | $13.2M | ||
| Q4 24 | $9.4M | $19.4M | ||
| Q3 24 | $4.0M | $110.7M | ||
| Q2 24 | $6.2M | $10.8M | ||
| Q1 24 | $1.4M | $9.1M |
| Q4 25 | $-131.8M | — | ||
| Q3 25 | $125.2M | $16.8M | ||
| Q2 25 | $16.6M | $-36.3M | ||
| Q1 25 | $-32.5M | $-41.0M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $-4.2M | $56.3M | ||
| Q2 24 | $-6.1M | $-55.7M | ||
| Q1 24 | $-5.4M | $-52.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 98.8% | ||
| Q3 24 | — | 99.8% | ||
| Q2 24 | — | 98.4% | ||
| Q1 24 | — | 97.0% |
| Q4 25 | -8.9% | -29.3% | ||
| Q3 25 | -3.1% | 25.6% | ||
| Q2 25 | -57.0% | -165.3% | ||
| Q1 25 | -394.6% | -323.1% | ||
| Q4 24 | 0.4% | -273.0% | ||
| Q3 24 | -79.1% | 48.9% | ||
| Q2 24 | -44.3% | -538.9% | ||
| Q1 24 | -205.2% | -590.4% |
| Q4 25 | -438.1% | — | ||
| Q3 25 | 246.4% | 23.1% | ||
| Q2 25 | 48.7% | -163.0% | ||
| Q1 25 | -400.5% | -311.1% | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | -104.2% | 50.9% | ||
| Q2 24 | -99.1% | -515.6% | ||
| Q1 24 | -398.0% | -573.3% |
| Q4 25 | $-6.94 | $-0.23 | ||
| Q3 25 | $7.27 | $0.27 | ||
| Q2 25 | $1.12 | $-0.57 | ||
| Q1 25 | $-3.02 | $-0.65 | ||
| Q4 24 | $0.21 | $-0.24 | ||
| Q3 24 | $-0.67 | $0.90 | ||
| Q2 24 | $-1.01 | $-0.89 | ||
| Q1 24 | $-0.91 | $-0.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $57.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $55.6M |
| Total Assets | $112.9M | $256.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $57.2M | ||
| Q3 25 | $176.2M | $80.1M | ||
| Q2 25 | $28.2M | $130.7M | ||
| Q1 25 | $18.9M | $145.6M | ||
| Q4 24 | $8.2M | $182.8M | ||
| Q3 24 | $7.2M | $179.6M | ||
| Q2 24 | $12.1M | $83.9M | ||
| Q1 24 | $7.1M | $80.4M |
| Q4 25 | $69.4M | $55.6M | ||
| Q3 25 | $210.2M | $67.0M | ||
| Q2 25 | $88.6M | $46.6M | ||
| Q1 25 | $42.4M | $79.1M | ||
| Q4 24 | $39.9M | $116.1M | ||
| Q3 24 | $38.3M | $120.1M | ||
| Q2 24 | $42.4M | $57.8M | ||
| Q1 24 | $47.7M | $106.2M |
| Q4 25 | $112.9M | $256.8M | ||
| Q3 25 | $223.4M | $270.8M | ||
| Q2 25 | $109.3M | $245.4M | ||
| Q1 25 | $52.3M | $224.6M | ||
| Q4 24 | $47.1M | $261.7M | ||
| Q3 24 | $43.4M | $264.5M | ||
| Q2 24 | $49.1M | $201.1M | ||
| Q1 24 | $52.2M | $248.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $43.0M |
| Free Cash FlowOCF − Capex | — | $42.8M |
| FCF MarginFCF / Revenue | — | 103.8% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-83.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $43.0M | ||
| Q3 25 | $-4.9M | $-30.2M | ||
| Q2 25 | $-353.0K | $-47.0M | ||
| Q1 25 | $1.2M | $-46.9M | ||
| Q4 24 | $-16.7M | $-38.4M | ||
| Q3 24 | $-4.7M | $60.2M | ||
| Q2 24 | $1.4M | $-44.5M | ||
| Q1 24 | $-8.6M | $-45.6M |
| Q4 25 | — | $42.8M | ||
| Q3 25 | — | $-30.6M | ||
| Q2 25 | — | $-47.7M | ||
| Q1 25 | — | $-47.4M | ||
| Q4 24 | — | $-39.0M | ||
| Q3 24 | — | $59.6M | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-47.1M |
| Q4 25 | — | 103.8% | ||
| Q3 25 | — | -42.0% | ||
| Q2 25 | — | -214.5% | ||
| Q1 25 | — | -359.5% | ||
| Q4 24 | — | -201.7% | ||
| Q3 24 | — | 53.8% | ||
| Q2 24 | — | -421.6% | ||
| Q1 24 | — | -517.4% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 4.0% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 9.6% | ||
| Q1 24 | — | 16.0% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | -1.79× | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
MGNX
| Revenue From Collaborative Agreements | $20.3M | 49% |
| Contract Manufacturing | $11.3M | 27% |
| Other | $9.7M | 23% |
